This company in competes some areas directly with the products...

This company in competes some areas directly with the products and distributors of SBN. Strangely enough they also don’t have a Saliva Drug Testing Product. Product sales accounted for 25% of total revenue in the 3 month period and Drugs-of-abuse testing services accounted for 50%. That is 15 million dollars revenue in 3 months.
If SBN can and do get their act together with both the Urine and Saliva testing!!! That is an indication of the potential!!!
The full article can be viewed at
http://www.msnbc.msn.com/id/29135735/
MEDTOX Scientific Announces Results for Fourth Quarter and Year-End 2008
Clinical Lab Revenue Increases 30.0% for the Quarter and 15.3% for the Year

ST. PAUL, Minn., Feb. 11, 2009 (GLOBE NEWSWIRE) -- MEDTOX Scientific, Inc. (Nasdaq:MTOX) today announced fourth quarter and year-end results for the periods ended December 31, 2008. MEDTOX achieved record revenues for the quarter and year-ended December 31, 2008.
For the three-month period, revenues were $20.8 million, compared to $19.7 million from the prior-year period. The Company recorded operating income of $1.1 million for the three-month period, compared to $1.9 million for the prior-year period. The Company recorded net income of $0.4 million for the three-month period, compared to $1.4 million for the prior-year period. Earnings per diluted share were $0.05, compared to $0.16 in the fourth quarter of 2007.
For the twelve month period, revenues were $85.8 million compared to $80.3 million for the prior-year period. The Company recorded operating income of $9.6 million for the twelve-month period, compared to $10.0 million for the prior-year period. The effective income tax rate for 2008 was 35.6% compared to an effective tax rate of 28.1% in 2007. The lower rate in 2007 equates to $0.08 per diluted share and was primarily due to a tax benefit from a favorable resolution of a state tax examination. The Company recorded net income of $5.6 million for 2008, compared to $6.7 million for the prior-year period. Earnings per diluted share were $0.62, compared to 2007 earnings per diluted share of $0.75.
ST. PAUL, Minn., Feb. 11, 2009 (GLOBE NEWSWIRE) -- MEDTOX Scientific, Inc. (Nasdaq:MTOX) today announced fourth quarter and year-end results for the periods ended December 31, 2008. MEDTOX achieved record revenues for the quarter and year-ended December 31, 2008.
For the three-month period, revenues were $20.8 million, compared to $19.7 million from the prior-year period. The Company recorded operating income of $1.1 million for the three-month period, compared to $1.9 million for the prior-year period. The Company recorded net income of $0.4 million for the three-month period, compared to $1.4 million for the prior-year period. Earnings per diluted share were $0.05, compared to $0.16 in the fourth quarter of 2007.
For the twelve month period, revenues were $85.8 million compared to $80.3 million for the prior-year period. The Company recorded operating income of $9.6 million for the twelve-month period, compared to $10.0 million for the prior-year period. The effective income tax rate for 2008 was 35.6% compared to an effective tax rate of 28.1% in 2007. The lower rate in 2007 equates to $0.08 per diluted share and was primarily due to a tax benefit from a favorable resolution of a state tax examination. The Company recorded net income of $5.6 million for 2008, compared to $6.7 million for the prior-year period. Earnings per diluted share were $0.62, compared to 2007 earnings per diluted share of $0.75.